Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-000162-42 | EudraCT Number |
Not provided
Not provided
Not provided
Slow recruitment due to COVID-19, the study was stopped when recruited numbers fulfilled the pre-defined lower sample size.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Type 2 diabetes is a major public health concern. It is widely established that type 2 diabetes in linked to activated innate immunity and increased levels of C-reactive protein and interleukin-6 (IL-6) in plasma. Studies in humans and in liver cells has shown that IL-6 downregulates important drug metabolizing enzymes in the liver (cytochrome P450 (CYP) enzymes). More than half of the most prescribed drugs are eliminated by biotransformation of these enzymes.
The investigators have previously shown that initiating glucose-lowering treatment (e.g. metformin, sulphonylureas and insulin) leads to decreased therapeutic efficacy of the blood-thinning vitamin-K antagonist warfarin. Due to the non-specific effect of glucose lowering drugs, the investigators hypothesize that this is caused by the glucose-lowering effect rather than drug-drug interactions caused by the individual drugs.
Based on the proposal that reversal of increased plasma glucose affects drug metabolism, the investigators will perform a clinical pharmacokinetic trial. The purpose of the study is to elucidate whether initiation of glucose-lowering treatment causes altered drug metabolism among patients with type 2 diabetes. The study will include newly diagnosed and untreated type 2 diabetes patients who will ingest a 6-drug cocktail consisting of probes for specific CYP enzymes. Plasma and urine will be drawn over 6 hours to determine concentrations of the drugs and their metabolites. Patients will then initiate metformin treatment and to assess both short- and long-term impact of glucose-lowering, the same 6-drug cocktail will be ingested, and concentrations measured, after three weeks and three months. To help understand the mechanism and the putative involvement of inflammation, markers of inflammation such as cytokines, transcription factors, etc. will also be assesses.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Metformin | Experimental | Patients will receive metformin 1000-2000 mg daily for 12 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Metformin | Drug | 500 mg tablet |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in Metabolic Rate of Midazolam (CYP3A4) at Week 3. | Change in activity of the drug metabolizing enzyme CYP3A4 following treatment with the glucose lowering drug metformin in 3 weeks. Assessment of the change is based on a change in the metabolic rate, which is the ratio between the concentration of midazolam and its primary metabolite is plasma (Probe drug for CYP3A4). | Baseline and Week 3. |
| Change from Baseline in Metabolic Rate of Midazolam (CYP3A4) at Week 12. | Change in activity of the drug metabolizing enzyme CYP3A4 following treatment with the glucose lowering drug metformin in 12 weeks. Assessment of the change is based on a change in the metabolic rate, which is the ratio between the concentration of midazolam and its primary metabolite is plasma (Probe drug for CYP3A4). | Baseline and Week 12. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in Metabolic Rate of Caffeine (CYP1A2) at Week 3. | Change in activity of the drug metabolizing enzymes CYP1A2 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug caffeine. | Baseline and Week 3. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ann-Cathrine Dunvald, MD | University of Southern Denmark | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Southern Denmark | Odense | Region Syddanmark | 5000 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26559049 | Background | Stage TB, Pottegard A, Henriksen DP, Christensen MM, Hojlund K, Brosen K, Damkier P. Initiation of glucose-lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a self-controlled register study. J Thromb Haemost. 2016 Jan;14(1):129-33. doi: 10.1111/jth.13187. Epub 2015 Dec 29. | |
| 36967527 |
Not provided
Not provided
Individual participant data cannot be shared due to general data protection regulation (GDPR).
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008687 | Metformin |
| D002110 | Caffeine |
| C098320 | efavirenz |
| D019808 | Losartan |
| D009853 | Omeprazole |
| D008790 | Metoprolol |
| D008874 | Midazolam |
| ID | Term |
|---|---|
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
| D014970 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Caffeine | Drug | As part of a 6-drug cocktail caffeine 100 mg tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP1A2 activity. |
|
| Efavirenz | Drug | As part of a 6-drug cocktail efavirenz 50 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2B6 activity. |
|
| Losartan | Drug | As part of a 6-drug cocktail losartan 12.5 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C9 activity. |
|
| Omeprazol | Drug | As part of a 6-drug cocktail Omeprazol 10 mg enteric-coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C19 activity. |
|
| Metoprolol | Drug | As part of a 6-drug cocktail metoprolol 12.5 mg release tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2D6 activity. |
|
| Midazolam | Drug | As part of a 6-drug cocktail midazolam 2 mg oral solution will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP3A4 activity. |
|
| Change from Baseline in Metabolic Rate of Caffeine (CYP1A2) at Week 12. |
Change in activity of the drug metabolizing enzymes CYP1A2 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug caffeine. |
| Baseline and Week 12. |
| Change from Baseline in Metabolic Rate of Efavirenz (CYP2B6) at Week 3. | Change in activity of the drug metabolizing enzymes CYP2B6 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Efavirenz. | Baseline and Week 3. |
| Change from Baseline in Metabolic Rate of Efavirenz (CYP2B6) at Week 12. | Change in activity of the drug metabolizing enzymes CYP2B6 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Efavirenz. | Baseline and Week 12. |
| Change from Baseline in Metabolic Rate of Losartan (CYP2C9) at Week 3. | Change in activity of the drug metabolizing enzymes CYP2C9 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Losartan. | Baseline and Week 3. |
| Change from Baseline in Metabolic Rate of Losartan (CYP2C9) at Week 12. | Change in activity of the drug metabolizing enzymes CYP2C9 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Losartan. | Baseline and Week 12. |
| Change from Baseline in Metabolic Rate of Omeprazole (CYP2C19) at Week 3. | Change in activity of the drug metabolizing enzymes CYP2C19 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Omeprazole. | Baseline and Week 3. |
| Change from Baseline in Metabolic Rate of Omeprazole (CYP2C19) at Week 12. | Change in activity of the drug metabolizing enzymes CYP2C19 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Omeprazole. | Baseline and Week 12. |
| Change from Baseline in Metabolic Rate of Metoprolol (CYP2D6) at Week 3. | Change in activity of the drug metabolizing enzymes CYP2D6 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Metoprolol. | Baseline and Week 3. |
| Change from Baseline in Metabolic Rate of Metoprolol (CYP2D6) at Week 12. | Change in activity of the drug metabolizing enzymes CYP2D6 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Metoprolol. | Baseline and Week 12. |
| Change from Baseline in HbA1c at Week 3. | Change in the regulation of blood glucose over time assessed by HbA1c | Baseline and Week 3. |
| Change from Baseline in HbA1c at Week 12. | Change in the regulation of blood glucose over time assessed by HbA1c | Baseline and Week 12. |
| Change from Baseline in insulin resistance at Week 3. | An oral glucose tolerance test will be performed and glucose, insulin and c-peptide will be measured and combined by the Homeostatic Model Assessment (HOMA) to report insulin resistance. | Baseline and Week 3. |
| Change from Baseline in insulin resistance at Week 12. | An oral glucose tolerance test will be performed and glucose, insulin and c-peptide will be measured and combined by the Homeostatic Model Assessment (HOMA) to report insulin resistance. | Baseline and Week 12. |
| Change from Baseline in Interleukin-1-B at Week 3. | Change in patients inflammatory status assessed by measurement of Interleukin-1-B. | Baseline and Week 3. |
| Change from Baseline in Interleukin-1-B at Week 12. | Change in patients inflammatory status assessed by measurement of Interleukin-1-B. | Baseline and Week 12. |
| Change from Baseline in Interleukin-2 at Week 3. | Change in patients inflammatory status assessed by measurement of Interleukin-2. | Baseline and Week 3. |
| Change from Baseline in Interleukin-2 at Week 12. | Change in patients inflammatory status assessed by measurement of Interleukin-2. | Baseline and Week 12. |
| Change from Baseline in Interleukin-6 at Week 3. | Change in patients inflammatory status assessed by measurement of Interleukin-6. | Baseline and Week 3. |
| Change from Baseline in Interleukin-6 at Week 12. | Change in patients inflammatory status assessed by measurement of Interleukin-6. | Baseline and Week 12. |
| Change from Baseline in Interleukin-10 at Week 3. | Change in patients inflammatory status assessed by measurement of Interleukin-10. | Baseline and Week 3. |
| Change from Baseline in Interleukin-10 at Week 12. | Change in patients inflammatory status assessed by measurement of Interleukin-10. | Baseline and Week 12. |
| Change from Baseline in Interferon-a at Week 3. | Change in patients inflammatory status assessed by measurement of Interferon-a. | Baseline and Week 3. |
| Change from Baseline in Interferon-a at Week 12. | Change in patients inflammatory status assessed by measurement of Interferon-a. | Baseline and Week 12. |
| Change from Baseline in Interferon-B at Week 3. | Change in patients inflammatory status assessed by measurement of Interferon-B. | Baseline and Week 3. |
| Change from Baseline in Interferon-B at Week 12. | Change in patients inflammatory status assessed by measurement of Interferon-B. | Baseline and Week 12. |
| Change from Baseline in Interferon-y at Week 3. | Change in patients inflammatory status assessed by measurement of Interferon-y. | Baseline and Week 3. |
| Change from Baseline in Interferon-y at Week 12. | Change in patients inflammatory status assessed by measurement of Interferon-y. | Baseline and Week 12. |
| Change from Baseline in Tumor Necrosis Factor-a at Week 3. | Change in patients inflammatory status assessed by measurement of Tumor Necrosis Factor-a. | Baseline and Week 3. |
| Change from Baseline in Tumor Necrosis Factor-a at Week 12. | Change in patients inflammatory status assessed by measurement of Tumor Necrosis Factor-a. | Baseline and Week 12. |
| Change from Baseline in High Sensitivity C-Reactive Protein at Week 3. | Change in patients inflammatory status assessed by measurement of High Sensitivity C-Reactive Protein. | Baseline and Week 3. |
| Change from Baseline in High Sensitivity C-Reactive Protein at Week 12. | Change in patients inflammatory status assessed by measurement of High Sensitivity C-Reactive Protein. | Baseline and Week 12. |
| Dunvald AD, Nielsen F, Olsen DA, Ernst MT, Donnelly L, Soto-Pedre E, Kristiansen MR, Nielsen JS, Persson F, Hojlund K, Madsen JS, Sondergaard J, Pearson E, Pottegard A, Stage TB. Initiation of glucose-lowering drugs reduces the anticoagulant effect of warfarin-But not through altered drug metabolism in patients with type 2 diabetes. Br J Clin Pharmacol. 2023 Aug;89(8):2529-2541. doi: 10.1111/bcp.15725. Epub 2023 Apr 14. |
| D004700 | Endocrine System Diseases |
| Xanthines |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D011688 | Purinones |
| D011687 | Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D001713 | Biphenyl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D013777 | Tetrazoles |
| D053799 | 2-Pyridinylmethylsulfinylbenzimidazoles |
| D013454 | Sulfoxides |
| D013457 | Sulfur Compounds |
| D011725 | Pyridines |
| D001562 | Benzimidazoles |
| D050198 | Phenoxypropanolamines |
| D011412 | Propanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D020005 | Propanols |
| D000588 | Amines |
| D001569 | Benzodiazepines |
| D001552 | Benzazepines |